Navigation Links
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
Date:6/7/2009

ride (8 mg, once daily) in patients with type 2 diabetes. Patients were treated previously with diet/exercise or low doses of one oral antidiabetic drug (OAD). The trial had a 52-week randomized, double-blind period followed by the one-year extension; 59% entered the extension period of the trial and 43% of these patients completed the full two-year study period.

LEAD(TM) 3: two-year data

    Two years                Liraglutide       Liraglutide       Glimepiride
     monotherapy             1.8 mg, QD        1.2 mg, QD        8 mg, QD
                             N=154             N=149             N=137

    Diabetes duration,
     years at baseline         5.0                5.0              5.0

    Previous treatment:
    % diet/exercise             35%                38%              34%
    % OAD monotherapy           65%                62%              66%

    A1C % at baseline          8.1                8.1              8.0

    BMI, kg/m(2) at
     baseline                   33                 33               33

    Change in A1C% from
     baseline                 -1.1               -0.9             -0.6

    Change in A1C%  from
     baseline (in
     patients with <3
     years duration of
     diabetes)                -1.4               -1.1             -0.7

    % A1C <7.0%                 58                 53               37

    Change FPG (Fasting
     Plasma Glucose)
     mg/dL from baseline       -27                -24               -6

    Weight change, kg
     from baseline            -2.7               -2.1              1.1

    Minor hypoglycemic
     events/patient/year      0.23               0.21             1.76

Safety and tolerability of liraglutide

The rate of minor hypoglycemia was statistically significantly lower with both liraglutide dose groups compared to the glimepiride-t
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
2. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
3. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
10. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
11. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Colo. , Dec. 15, 2014  The Government of ... collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT to ... , as well as provide long-term health system capacity to ... Facts: , The Ghanaian Ebola Readiness and Resilience Initiative ... Ghana,s preparations for the possible arrival of the ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/2r6bmg/drug_injection ... "Drug Injection Devices to 2020" report to ... As new drugs become available ... health conditions, drug developers have increasingly pursued packaging ... and increase the efficiency and reliability with which ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha ... the HiSeq X Ten sequencing system manufactured by ... HudsonAlpha to produce and analyze genomic data faster ... from the Institute,s commitment to research programs for ... HiSeq X Ten provides unprecedented capacity, speed and ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Overactive Bladder Treatment for... -- ARDEE, Ireland, Oct. 18 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Medicine Technology:Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 2Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 3Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 4Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 5Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 6Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 7Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 8Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 9Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 2Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 3Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 4Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 5Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 6Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 7Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 8
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... pilots process visual information more efficiently than less experienced ... landings, a new study shows. Landing is one ... and 36 percent of all airplane crashes and 25 ... landing. Researchers monitored the brain activity of eight ... were at the controls of a flight simulator. As ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... molecules found in certain plants appears to have a beneficial ... a new study conducted in mice. The study was led ... Medical Center. An article in the Journal of Cellular and ... of the senior authors of the study, is available to ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin ... of healthcare related disinfectants in China,announced today ... Hi-Tech Company, Ltd., (LiKang Disinfectant) began training,and ... Olympics. The project,is sponsored by and under ...
... to Provide ... for Their Families, CHICAGO, May 7 Mother,s Day is ... gatherings and gifts,and to honor those who give so much to their families ... of those mothers who,live in poverty and need the assistance of programs offered ...
... Emory Winship Cancer Institute, ATLANTA, May 7 ... commitment of $50,000 to the Emory Winship Cancer ... southeast focused on,triple-negative breast cancer research. Dan Amos, ... president, made the personal donation,in honor of the ...
... The Female Health Company,(Amex: FHC ) today ... discuss its operating results for the second quarter of ... 14, 2008. The Company plans to,report its second quarter ... and other interested parties may participate in the,conference call ...
... Highlighted, TAMPA, Fla., May 7 Acute pain ... than 25 million,Americans are said to experience acute pain ... a recent study estimated that 42 percent of U.S.,hospital ... Seven clinical presentations on tapentadol immediate release (IR),tablets for ...
Cached Medicine News:Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 2Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 3Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 4Health News:Catholic Charities Calls for Increased Support of Mothers in Need: 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 3Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 4
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: